FDG PET/CT in the detection of recurrent rectal cancer

International Surgery

Volumn 94, Issue 4, 2009, Pages 315-324

  Kau, Thomas ^a   Reinprecht, Peter ^a   Eicher, Wolfgang ^a   Lind, Peter ^a   Starlinger, Michael ^a   Hausegger, Klaus Armin ^a  

^a GENERAL HOSPITAL KLAGENFURT   (Austria)

Author keywords

FDG PET CT; Imaging follow up; Positron emission tomography; Rectal cancer

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CHI SQUARE DISTRIBUTION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; RADIOGRAPHY; RECTUM TUMOR; RETROSPECTIVE STUDY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; CHI-SQUARE DISTRIBUTION; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 77749237123     PISSN: 00208868     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Wibe A, Syse A, Andersen E, Tretli S, Myrvold HE, Soreide O. Oncological outcomes after total mesorectal excision for cure for cancer of the lower rectum: anterior vs. abdominoperineal resection. Dis Colon Rectum 2004;47:48-58
2. Huguier M, Houry S, Barrier A. Local recurrence of cancer of the rectum. Am J Surg 2001;182:437-439
3. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-1740
4. Marr R, Birbeck K, Garvican J, Garvican J, Macklin CP, Tiffin NJ, et al. The modern abdominoperineal excision: the next challenge after total mesorectal excision. Ann Surg 2005;242:74-82
5. Biondo S, Navarro M, Marti-Rague J, Arriola E, Pares D, Del Rio C, et al. Response to neoadjuvant therapy for rectal cancer: influence on long-term results. Colorectal Dis 2005;7:472-479
6. Israel O, Mor M, Guralnik L, Hermoni M, Gaitini D, Bar-Shalom R, et al. Is 18F-FDG PET/CT useful for imaging and management of patients with suspected occult recurrence of cancer? J Nucl Med 2004;45:2045- 2051
7. Kalff V, Hicks RJ, Ware RE, Hogg A, Binns D, McKenzie AF. The clinical impact of (18)F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. J Nucl Med 2002;43:492-499
8. Kostakoglu L, Hardoff R, Mirtcheva R, Goldsmith SJ. PET-CT fusion imaging in differentiating physiologic from pathologic FDG uptake. Radiographics 2004;24:1411-1431
9. Even-Sapir E, Parag Y, Lerman H, Gutman M, Levine C, Rabau M, et al. Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection. Radiology 2004;232:815-622
10. Townsend DW. A combined PET/CT scanner: the choices. J Nucl Med 2001;42:533-534
11. Rosenbaum SJ, Lind T, Antoch G, Bockisch A. False positive FDG PET uptake - the role of PET/CT. Eur Radiol 2005;17:1-12
12. Francis IR, Brown RK, Avram AM. The clinical role of CT/PET in oncology: an update. Cancer Imaging 2005;5:S68-S75
13. Doerfler OC, Ruppert-Kohlmayr RJ, Reittner P, Hinterleitner T, Petritsch W, Szolar DH. Helical CT of the small bowel with an alternative oral contrast material in patients with Crohn disease. Abdom Imaging 2003;28:313-318
14. Reittner P, Goritschnig T, Petritsch W, Doerfler O, Preidler KW, Hinterleitner T, et al. Multiplanar spiral CT enterography in patients with Crohn's disease using a negative oral contrast material: initial results of a noninvasive imaging approach. Eur Radiol 2002;12:2253-2257
15. Antoch G, Kuehl H, Kanja J, Lauenstein TC, Schneemann H, Hauth E, et al. Dual-modality PET/CT scanning with negative oral contrast agent to avoid artifacts: introduction and evaluation. Radiology 2004;230:879- 885
16. Hausegger KA, Reinprecht T, Kau T, Igerc I, Lind P. Clinical experience with a commercially available negative oral contrast medium in PET/CT. Rofo 2005;177:796-799
17. Nomori H, Watanabe K, Ohtsuka T, Naruke T, Suemasu K, Uno K. Visual and semiquantitative analyses for F-18 fluorodeoxyglucose PET scanning in pulmonary nodules 1 cm to 3 cm in size. Ann Thorac Surg 2005;79:984-989
18. Lerman H, Metser U, Grisaru D, Fishman A, Lievshitz G, Even-Sapir E. Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: assessment by PET/CT. J Nucl Med 2004;45:266-271
19. Delbeke D, Martin WH. Metabolic imaging with FDG: a primer. Cancer J 2004;10:201-213
20. Dent OF, Chapuis PH, Bokey EL, Newland RC. Methodology and reporting in studies of local recurrence after curative excision of the rectum for cancer. Br J Surg 2001;88:1476-1480
21. Wiig JN, Larsen SG, Giercksky KE. Operative treatment of locally recurrent rectal cancer. Recent Results Cancer Res 2005;165:136- 147
22. Boyle KM, Sagar PM, Chalmers AG, Sebag-Montefiore D, Cairns A, Eardley I. Surgery for locally recurrent rectal cancer. Dis Colon Rectum 2005;48:929-937
23. Reerink O, Mulder NH, Botke G, Sluiter WJ, Szabo BG, Plukker JT, et al. Treatment of locally recurrent rectal cancer, results and prognostic factors. Eur J Surg Oncol 2004;30:954-958
24. Jeffery GM, Hickey BE, Hider P. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev 2002;CD002200
25. Imbriaco M, Akhurst T, Hilton S, Yeung HW, Macapinlac HA, Mazumdar M, et al. Whole-body FDG-PET in patients with recurrent colorectal carcinoma: a comparative study with CT. Clin Positron Imaging 2000;3:107-114
26. Desai DC, Zervos EE, Arnold MW, Burak WE Jr, Mantil J, Martin EW Jr. Positron emission tomography affects surgical management in recurrent colorectal cancer patients. Ann Surg Oncol 2003;10:59-64
27. Fukunaga H, Sekimoto M, Ikeda M, Higuchi I, Yasui M, Seshimo I, et al. Fusion image of positron emission tomography and computed tomography for the diagnosis of local recurrence of rectal cancer. Ann Surg Oncol 2005;12:561-569
28. Strunk H, Bucerius J, Jaeger U, Joe A, Flacke S, Reinhardt M, et al. Combined FDG PET/CT imaging for restaging of colorectal cancer patients: impact of image fusion on staging accuracy. Rofo 2005;177:1235- 1241
29. Vogel VW, Wiering B, Corstens FH, Ruers TJ, Oyen WJ. Colorectal cancer: the role of PET/CT in recurrence. Cancer Imaging 2005;5:S143-S149
30. Kim JH, Czernin J, Allen-Auerbach MS, Halpem BS, Fueger BJ, Hecht JR, et al. Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer. J Nucl Med 2005;46:587-595
31. Ito K, Kato T, Tadokoro M, Yameda T, Ikeda M, Nishino M, et al. Recurrent rectal cancer and scar: differentiation with PET and MR imaging. Radiology 1992;182:549-552
32. Bagheri B, Maurer AH, Cone L, Doss M, Adler L. Characterization of the normal adrenal gland with 18F-FDG PET/CT. J Nucl Med 2004;45:1340- 1343
33. Maurea S, Klain M, Mainolfi C, Ziviello M, Salvatore M. The diagnostic role of radionuclide imaging in evaluation of patients with nonhypersecreting adrenal masses. J Nucl Med 2001;42:884-892
34. Frilling A, Tecklenborg K, Weber F, Kuhl H, Muller S, Stamatis G, et al. Importance of adrenal incidentaloma in patients with a history of malignancy. Surgery 2004;136:1289-1296
35. Rao SK, Caride VJ, Ponn R, Giakovis E, Lee SH. F-18 fluorodeoxyglucose positron emission tomography-positive benign adrenal cortical adenoma: imaging features and pathologic correlation. Clin Nucl Med 2004;29:300-302
36. Shimizu A, Oriuchi N, Tsushima J, Higuchi T, Endo K. High [18F] 2-fluoro-2-deoxy-D-glucose (FDG) uptake of adrenocortical adenoma showing subclinical Cushing's syndrome. Ann Nucl Med 2003;17:403-406
37. Jana S, Zhang T, Milstein DM, Isasi CR, Blaufox MD. FDG-PET and CT characterization of adrenal lesions in cancer patients. Eur J Nucl Med Mol Imaging 2006;33:29-35
38. Metser U, Miller E, Lerman H, Lievshitz G, Avital S, Even-Sapir E. 18F-FDG PET/CT in the evaluation of adrenal masses. J Nucl Med 2006;47:32-37
39. Leslie A, Carey FA, Pratt NR, Steele RJ. The colorectal adenoma-carcinoma sequence. Br J Surg 2002;89:845-860
40. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-767
41. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature 1997;386:623-627
42. Yasuda S, Fujii H, Nakahara T, Nishiumi N, Takahashi W, Ide M, et al. 18F-FDG PET detection of colonic adenomas. J Nucl Med 2001;42:989-992
43. Van Kouwen MC, Nagengast FM, Jansen JB, Oyen WJ, Drenth JP. 2-(18F)-fluoro-2-deoxy-D-glucose positron emission tomography detects clinical relevant adenomas of the colon: a prospective study. J Clin Oncol 2005;23:3713-3717
44. Friedland S, Soetikno R, Carlisle M, Taur A, Kaltenbach T, Segall G. 18-Fluorodeoxyglucose positron emission tomography has limited sensitivity for colonic adenoma and early stage colon cancer. Gastrointest Endosc 2005;61:395-400
45. Arslan N, Dehdashti F, Siegel BA. FDG uptake in colonic villous adenomas. Ann Nucl Med 2005;19:331-334
46. Rosenbaum SJ, Stergar H, Antoch G, Veit P, Bockisch A, Kuhl H. Staging and follow-up of gastrointestinal tumors with PET/CT. Abdom Imaging 2006;31:25-35